ZVRA Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. (ZVRA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 94% planned / 6% discretionary
Largest single sale: $853.4K.
Where they traded
Last open-market purchase: September 12, 2025 — 1.0 years ago, by FAVORITO TAMARA A .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Thompson Rahsaan | Chief Legal & Compliance | Sell 10b5-1 | 42,666 | $11.13 | $474.8K | 37,569 −53.2% of holding | |
| Watton Corey Michael | Director | Sell | 12,300 | $11.25 | $138.4K | 1,800 −87.2% of holding | |
| Thompson Rahsaan | Chief Legal & Compliance | Sell 10b5-1 | 34,557 | $12.68 | $438.3K | 80,235 −30.1% of holding | |
| Thompson Rahsaan | Chief Legal & Compliance | Sell 10b5-1 | 1,794 | $11.30 | $20.3K | 48,125 −3.6% of holding | |
| McFarlane Neil F. | President and CEO | Sell 10b5-1 | 14,625 | $8.56 | $125.2K | 387,225 −3.6% of holding | |
| Schafer Joshua | CCO | Sell 10b5-1 | 10,500 | $9.19 | $96.5K | 62,278 −14.4% of holding | |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Sell 10b5-1 | 3,000 | $9.18 | $27.5K | 29,590 −9.2% of holding | |
| McFarlane Neil F. | President and CEO | Sell 10b5-1 | 91,000 | $9.38 | $853.4K | 364,350 −20% of holding | |
| Quartel Adrian W | Chief Medical Officer | Sell 10b5-1 | 4,533 | $8.83 | $40.0K | 9,723 −31.8% of holding | |
| Thompson Rahsaan | Chief Legal & Compliance | Sell 10b5-1 | 4,080 | $8.83 | $36.0K | 49,919 −7.6% of holding | |
| Schafer Joshua | CCO | Sell 10b5-1 | 3,375 | $8.83 | $29.8K | 37,444 −8.3% of holding | |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Sell 10b5-1 | 1,750 | $8.82 | $15.4K | 20,924 −7.7% of holding | |
| McFarlane Neil F. | President and CEO | Sell 10b5-1 | 19,500 | $10.82 | $210.9K | 222,016 −8.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.